Navigation Links
LA BioMed's Dr. John Tsuang examines effects of Ibudilast and metamphetamines
Date:4/25/2012

LOS ANGELES (April 25, 2012) John W. Tsuang, M.D., principal investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), in conjunction with Steven J. Shoptaw, Ph.D., from the UCLA Department of Family Medicine, is spearheading a Phase I clinical safety trial that for the first time examines the effects of Ibudilast when administered with metamphetamine (MA), an addictive stimulant that is closely related to amphetamine. Ibudilast is a non-selective phosphodiesterase inhibitor known as a modulator of glial activation in the central nervous system; the role of these glial cells is to regulate the repair of neurons after an injury, such as the neurocognitive deficits caused by long-term MA addiction. The study is being funded by the National Institutes of Health National Institute on Drug Abuse (NIDA).

More commonly known as "speed," "meth" or "ice," MA is long lasting and toxic to dopamine nerve terminals in the central nervous system (NIDA). According to the Substance Abuse and Mental Health Services Administration (SAMHSA), a 2009 survey revealed that 1.2 million Americans ages 12 and older had abused MA at least once prior to the year they were surveyed. According to the SAMHSA, MA dependence causes devastating personal and public health consequences, particularly in the Western and Midwestern United States.

"Currently, there are no approved medications to help treat MA dependence," said Dr. Tsuang. "Through this study, we are working to determine the effects of Ibudilast - combined with relevant doses of MA - on heart rate and blood pressure, and whether or not Ibudilast alters the way in which the body absorbs, distributes, and metabolizes MA. The development of one or more medications to reduce MA abuse, when implemented with evidence-based behavioral and counseling interventions, would have obvious public health significance."

Dr. Tsuang and his colleagues are utilizing a randomized double-blind, placebo-controlled within-subject crossover design to determine the safety and tolerability and subjective and reinforcing effects of MA in 12 participants who are not seeking treatment for MA dependence. The participants will be treated with oral Ibudilast (20mg BID and 50mg BID) and placebo.

Recent research suggests that glial cells may be important in modulating the rewarding properties of drugs that are abused, including MA. Research also suggests that MA-induced glial activation may help reduce the damage done to the central nervous system and associated cognitive dysfunction via glial cell secretion of pro-inflammatory cytokines, which are proteins that interact with cells of the immune system in order to regulate the body's response to disease and infection.

Dr. Tsuang is hoping that following the initial safety trial, physicians will be able to utilize Ibudilast in treating patients with MA dependence to help them improve memory and reduce the damage done to their central nervous system due to MA abuse.


'/>"/>

Contact: Diana Soltesz
diana@dsmmedia.com
818-592-6747
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. Ming T. Tsuang recognized with NARSAD outstanding achievement award for schizophrenia research
2. New Research Examines Impact of Health Care Reform on Regional Health Plans
3. New national study examines weight training-related injuries
4. Cedars-Sinai study examines regional use of minimally invasive repair of aneurysms
5. AERA journal examines research issues
6. CWRU study examines effectiveness of telemonitoring vital signs
7. AP-CNBC Poll Examines "Marijuana & Money"
8. DSM Personalized Nutrition Webinar Examines Ways to Build Engagement in Wellness Programs
9. Study examines global availability of treatment involving transplantation of blood stem cells
10. Wednesday, May 26: Forum Examines State of Literacy In Connecticut
11. UAB study examines hearing loss, Viagra use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... Access ... & Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) ... widely used electronic patient signatures solution in healthcare . , Since it ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended CHI's 8th ... of clinical trial planning and management. Pharmica discussed the importance of effective project ... attendees stopping by Pharmica’s booth were able to demo its cloud-based Resource ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... Like most ... reduce readmissions. Driven in large part by the Hospital Readmission Reduction Program (HRRP), the ... a key focus area for hospitals across the nation. While many providers are struggling ...
(Date:2/17/2017)... ... February 17, 2017 , ... Dillon Ruxton Insurance, a Florida-based ... owners in the greater Fort Lauderdale metropolitan region, is embarking on a cooperative ... 30 years, LifeNet 4 Families has provided a broad range of food provision ...
(Date:2/16/2017)... , ... February 17, 2017 , ... Teaching nursing care ... program, now in development. ACE.P (pediatrics) is being created with the support of the ... of Vulnerable Populations , ACE.P will address what has been identified as a critical ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... ST. LOUIS , Feb. 17, 2017   ... hospitals, has announced a new partnership with Engage ... the United States . FormFast will serve ... part of Engage,s implementations with MEDITECH .  ... that provides essential functionality to complement and enhance the ...
(Date:2/16/2017)... Pa. , Feb. 16, 2017 Absorption ... biologics, and medical devices, is pleased to announce that ... has been selected as a winner of the 2017 ... SmartCEO Magazine and recognizes driven executives for their ... work ethic. The awards ceremony and celebration is on ...
(Date:2/16/2017)... , Feb. 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company, today announced that executive management will participate ... be held February 22-23, 2017. Adrian Adams , ... Company at 1:35 p.m. local time on Wednesday, February ... archive for the event may be accessed from the ...
Breaking Medicine Technology: